CMS Finalizes Rule to Standardize Electronic Claims Attachments and Signatures

• New national polls from KFF and West Health-Gallup show Americans cutting back on health care, including rationing medications, to afford rising costs affecting daily living and access. • Millions express worry about affording emergency services, routine visits, and prescription drugs, leading to dangerous health trade-offs. • US physicians report higher burnout, stress, and dissatisfaction than international peers, with female doctors at greater risk and shortages projected at 40,000 primary care doctors by 2036.

• Perplexity AI introduced Perplexity Health on March 23, 2026, enabling users to connect provider health information via B.Well alongside data from Apple Health, Fitbit, and Withings. • The dashboard tracks personal health metrics and answers questions based on individual user data using AI-powered search capabilities. • This tool addresses growing demand for accessible health data integration amid criticisms of inaccurate crowdsourced medical advice from platforms like Google.

• Researchers from Harvard T.H. Chan School of Public Health published findings on March 19 in Environmental Health Perspectives linking fine particulate matter (PM2.5) exposure to a 3.2% increase in cardiovascular hospital admissions within two days in major US metropolitan areas. • The analysis of 15 million hospital records across 50 US cities over 12 years found that a 10 microgram per cubic meter increase in PM2.5 correlates with approximately 4,200 additional cardiovascular hospitalizations annually across studied cities. • The research supports EPA air quality standards and highlights urgent need for pollution control measures, as cardiovascular disease remains the leading cause of death in the United States affecting 126 million Americans.

• The National Institutes of Health announced a five-year, $450 million research initiative on March 21 to develop new antibiotics and diagnostic tools for antimicrobial-resistant infections. • The program will fund 75 research projects across 40 institutions, focusing on drug-resistant pathogens including carbapenem-resistant Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA). • Antimicrobial resistance causes an estimated 35,000 deaths annually in the United States, with the CDC warning of a potential 'silent pandemic' without intervention.

• A Phase 2 clinical trial led by Memorial Sloan Kettering Cancer Center demonstrated that engineered CAR-T cells targeting mesothelin showed a 52% overall response rate in 89 patients with advanced pancreatic and ovarian cancers. • The trial, results published March 19 in Cancer Cell, showed durable responses lasting over one year in 68% of responding patients, compared to historical response rates below 20% with conventional chemotherapy. • CAR-T therapy has revolutionized blood cancer treatment but remained ineffective against solid tumors until recent engineering advances, potentially opening a new therapeutic avenue for 400,000 Americans diagnosed with pancreatic and ovarian cancers annually.

• The Department of Health and Human Services announced expanded telehealth reimbursement policies effective immediately, allowing federally qualified health centers in rural areas to bill for remote patient monitoring services at 80% of in-person rates. • The rule change aims to address healthcare disparities in 60 million rural Americans by enabling chronic disease management and specialist consultations without travel barriers, with CMS projecting 2.3 million rural patients will gain access to remote care. • Studies show telehealth reduces healthcare costs by 15-20% while maintaining clinical quality, with rural adoption rates currently at 12% compared to 38% in urban areas.

• Respiratory syncytial virus (RSV) hospitalizations declined 42% in the week ending March 20, 2026, compared to the peak surge in February, according to CDC surveillance data. • The decline follows the introduction of the first RSV vaccines approved for adults over 60 and high-risk populations, with over 8 million doses administered since January. • RSV typically causes severe disease in infants and older adults; the new vaccines represent a major breakthrough after decades of failed vaccine development efforts.

• The FDA granted accelerated approval to a novel immunotherapy combination for metastatic pancreatic cancer on March 21, 2026, based on Phase 2 trial data showing a 35% response rate. • The drug combination demonstrated a median overall survival of 14.2 months compared to 11.8 months with standard chemotherapy in the clinical trial of 280 patients. • Pancreatic cancer remains one of the deadliest cancers with a five-year survival rate below 12%, making this approval potentially significant for the estimated 64,000 Americans diagnosed annually.

• Researchers at Johns Hopkins University published findings in Nature Medicine on March 20 showing a blood test can detect Alzheimer's pathology 15-20 years before symptom onset with 94% accuracy. • The test measures phosphorylated tau and amyloid-beta levels and was validated in 2,100 cognitively normal participants followed for up to 12 years in multiple longitudinal cohorts. • Early detection could enable preventive interventions during the asymptomatic stage, potentially delaying or preventing cognitive decline in the 6 million Americans living with Alzheimer's disease.

• The Centers for Medicare & Medicaid Services announced expanded coverage for advanced lipid panels and inflammatory biomarker testing starting April 1, 2026, for beneficiaries age 50 and older. • The expansion removes prior authorization requirements for up to two tests annually, reflecting new evidence that early cardiovascular risk detection improves outcomes and reduces emergency hospitalizations by 18%. • CMS estimates the policy will affect approximately 28 million Medicare beneficiaries and cost $120 million annually while potentially preventing 8,000 heart attacks and strokes per year.

• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.